Palivizumab: an overview
- PMID: 10707171
- DOI: 10.12968/hosp.1999.60.12.1254
Palivizumab: an overview
Abstract
Respiratory syncytial virus (RSV) affects almost all children in their first 2 years of life and can cause severe or even life-threatening disease in some at-risk infants. Treatment is limited and there is currently no safe or effective vaccine. However, a new monoclonal antibody, palivizumab, reduces RSV hospitalization by 55% in at-risk groups if given prophylactically throughout the RSV season.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical